Treeline Biosciences

forest

Biotech

Treeline sees path to public markets via reverse merger

The deal is expected to close in the second half of this year and should leave Treeline with $900 million in cash, enough to last into 2029.

Darren Incorvaia Jun 8, 2026 10:37am

Apple trees in an orchard

Treeline reaps $200M series A extension, picks first 3 programs

Sep 3, 2025 11:15am

The Top Line

A look at biotech's biggest money raisers of 2024

Mar 7, 2025 9:00am

biotechs top money raisers hero image

Biotech's top money raisers: 2024

Mar 3, 2025 5:00am

Parachute

Lilly, Novartis R&D vets forge cancer biotech—Chutes & Ladders

Apr 30, 2021 9:30am

Josh Bilenker

Ex-Lilly R&D lead launches cancer biotech with Novartis alum

Apr 27, 2021 7:20am